137 related articles for article (PubMed ID: 25849870)
21. Cell membrane gp96 facilitates HER2 dimerization and serves as a novel target in breast cancer.
Li X; Sun L; Hou J; Gui M; Ying J; Zhao H; Lv N; Meng S
Int J Cancer; 2015 Aug; 137(3):512-24. PubMed ID: 25546612
[TBL] [Abstract][Full Text] [Related]
22. Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum.
Ruiz-Saenz A; Sandhu M; Carrasco Y; Maglathlin RL; Taunton J; Moasser MM
Oncogene; 2015 Oct; 34(41):5288-94. PubMed ID: 25619841
[TBL] [Abstract][Full Text] [Related]
23. Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
Bessette DC; Tilch E; Seidens T; Quinn MC; Wiegmans AP; Shi W; Cocciardi S; McCart-Reed A; Saunus JM; Simpson PT; Grimmond SM; Lakhani SR; Khanna KK; Waddell N; Al-Ejeh F; Chenevix-Trench G
PLoS One; 2015; 10(5):e0125232. PubMed ID: 25969993
[TBL] [Abstract][Full Text] [Related]
24. Bifunctional fused polypeptide inhibits the growth and metastasis of breast cancer.
Liang AL; Qian HL; Zhang TT; Zhou N; Wang HJ; Men XT; Qi W; Zhang PP; Fu M; Liang X; Lin C; Liu YJ
Drug Des Devel Ther; 2015; 9():5671-86. PubMed ID: 26527862
[TBL] [Abstract][Full Text] [Related]
25. Silencing human epidermal growth factor receptor-3 radiosensitizes human luminal A breast cancer cells.
He G; Di X; Yan J; Zhu C; Sun X; Zhang S
Cancer Sci; 2018 Dec; 109(12):3774-3782. PubMed ID: 30259607
[TBL] [Abstract][Full Text] [Related]
26. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
27. A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance.
Al-Akhrass H; Conway JRW; Poulsen ASA; Paatero I; Kaivola J; Padzik A; Andersen OM; Ivaska J
Oncogene; 2021 Feb; 40(7):1300-1317. PubMed ID: 33420373
[TBL] [Abstract][Full Text] [Related]
28. A bispecific HER2-targeting FynomAb with superior antitumor activity and novel mode of action.
Brack S; Attinger-Toller I; Schade B; Mourlane F; Klupsch K; Woods R; Hachemi H; von der Bey U; Koenig-Friedrich S; Bertschinger J; Grabulovski D
Mol Cancer Ther; 2014 Aug; 13(8):2030-9. PubMed ID: 24994770
[TBL] [Abstract][Full Text] [Related]
29. Profiling the HER3/PI3K pathway in breast tumors using proximity-directed assays identifies correlations between protein complexes and phosphoproteins.
Mukherjee A; Badal Y; Nguyen XT; Miller J; Chenna A; Tahir H; Newton A; Parry G; Williams S
PLoS One; 2011 Jan; 6(1):e16443. PubMed ID: 21297994
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV.
Schmitt LC; Rau A; Seifert O; Honer J; Hutt M; Schmid S; Zantow J; Hust M; Dübel S; Olayioye MA; Kontermann RE
MAbs; 2017 Jul; 9(5):831-843. PubMed ID: 28421882
[TBL] [Abstract][Full Text] [Related]
31. Targeting HER3 for cancer treatment: a new horizon for an old target.
Uliano J; Corvaja C; Curigliano G; Tarantino P
ESMO Open; 2023 Feb; 8(1):100790. PubMed ID: 36764093
[TBL] [Abstract][Full Text] [Related]
32. Serotonergic system antagonists target breast tumor initiating cells and synergize with chemotherapy to shrink human breast tumor xenografts.
Gwynne WD; Hallett RM; Girgis-Gabardo A; Bojovic B; Dvorkin-Gheva A; Aarts C; Dias K; Bane A; Hassell JA
Oncotarget; 2017 May; 8(19):32101-32116. PubMed ID: 28404880
[TBL] [Abstract][Full Text] [Related]
33. NRG-1 Stimulates Serum DJ-1 Increase in Breast Cancers.
Wang Y; Zhang Y; Lu Q; Wang Y; Sun X; Zhang S
Pathol Oncol Res; 2019 Jan; 25(1):71-79. PubMed ID: 28963699
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological targeting of the pseudokinase Her3.
Xie T; Lim SM; Westover KD; Dodge ME; Ercan D; Ficarro SB; Udayakumar D; Gurbani D; Tae HS; Riddle SM; Sim T; Marto JA; Jänne PA; Crews CM; Gray NS
Nat Chem Biol; 2014 Dec; 10(12):1006-12. PubMed ID: 25326665
[TBL] [Abstract][Full Text] [Related]
35. Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody.
Meneses-Lorente G; Friess T; Kolm I; Hölzlwimmer G; Bader S; Meille C; Thomas M; Bossenmaier B
Cancer Chemother Pharmacol; 2015 Apr; 75(4):837-50. PubMed ID: 25702049
[TBL] [Abstract][Full Text] [Related]
36. HER3 as a Therapeutic Target in Cancer.
Karachaliou N; Lazzari C; Verlicchi A; Sosa AE; Rosell R
BioDrugs; 2017 Feb; 31(1):63-73. PubMed ID: 28000159
[TBL] [Abstract][Full Text] [Related]
37. Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification.
Malm M; Kronqvist N; Lindberg H; Gudmundsdotter L; Bass T; Frejd FY; Höidén-Guthenberg I; Varasteh Z; Orlova A; Tolmachev V; Ståhl S; Löfblom J
PLoS One; 2013; 8(5):e62791. PubMed ID: 23675426
[TBL] [Abstract][Full Text] [Related]
38. The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.
Kodack DP; Askoxylakis V; Ferraro GB; Sheng Q; Badeaux M; Goel S; Qi X; Shankaraiah R; Cao ZA; Ramjiawan RR; Bezwada D; Patel B; Song Y; Costa C; Naxerova K; Wong CSF; Kloepper J; Das R; Tam A; Tanboon J; Duda DG; Miller CR; Siegel MB; Anders CK; Sanders M; Estrada MV; Schlegel R; Arteaga CL; Brachtel E; Huang A; Fukumura D; Engelman JA; Jain RK
Sci Transl Med; 2017 May; 9(391):. PubMed ID: 28539475
[TBL] [Abstract][Full Text] [Related]
39. Mechanism underlying resveratrol's attenuation of paclitaxel cytotoxicity in human breast cancer cells: Role of the SIRT1-FOXO1-HER3 signaling pathway.
Fukui M; Choi HJ; Wang P; Zhu BT
Cancer Treat Res Commun; 2021; 28():100386. PubMed ID: 34010730
[TBL] [Abstract][Full Text] [Related]
40. Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics.
Sims JD; Taguiam JM; Alonso-Valenteen F; Markman J; Agadjanian H; Chu D; Lubow J; Abrol R; Srinivas D; Jain A; Han B; Qu Y; Mirzadehgan P; Hwang JY; Rentsendorj A; Chung A; Lester J; Karlan BY; Gray HB; Gross Z; Giuliano A; Cui X; Medina-Kauwe LK
J Control Release; 2018 Feb; 271():127-138. PubMed ID: 29288681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
